Amlypave (anselamimab)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- anselamimab
- Company
- Alexion Europe
- Status
- Application withdrawn
- Therapeutic area
- Immunoglobulin Light-chain Amyloidosis
- Designations
- Orphan
- Application
- EMEA/H/C/006422
- ATC
- B06AX
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with kappa light chain amyloidosis.
Regulatory milestones
Fri 30 Oct 2026🇪🇺 Application withdrawn (EU)
Amlypave (anselamimab): EU application withdrawn
Follow Amlypave
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.